Updating the role of natriuretic peptide levels in cardiovascular disease

Postgraduate Medicine

Volumn 123, Issue 6, 2011, Pages 102-113

  Gopal, Dipika J ^a   Iqbal, M N ^a   Maisel, Alan ^a  

^a UCSD MEDICAL CENTER   (United States)

Author keywords

B type natriuretic peptide; B type natriuretic peptide N terminal pro B natriuretic peptide guided therapy; Clinical applications; Diagnosis; N terminal pro B natriuretic peptide; Natriuretic peptides; Prognosis

Indexed keywords

ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOOP DIURETIC AGENT; NATRIURETIC FACTOR; PLACEBO; SPIRONOLACTONE; VALSARTAN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADVERSE OUTCOME; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL DECISION MAKING; CONGESTIVE HEART FAILURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIASTOLIC DYSFUNCTION; DISEASE COURSE; DISEASE EXACERBATION; DYSPNEA; EVENT FREE SURVIVAL; FUNCTIONAL ASSESSMENT; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE OVERLOAD; HOSPITAL READMISSION; HUMAN; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PATIENT MONITORING; POINT OF CARE TESTING; PREDICTIVE VALUE; PROGNOSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SCREENING; SENSITIVITY AND SPECIFICITY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTOLIC DYSFUNCTION; VALVULAR HEART DISEASE;

ACUTE CORONARY SYNDROME; BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; HEART FAILURE; HEART VALVE DISEASES; HUMANS; MASS SCREENING; MONITORING, PHYSIOLOGIC; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 82155189007     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2011.11.2500     Document Type: Article

References (62)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation. 2011;123(4):e18-e209.
2. Remes J, Miettinen H, Reunanen A, Pyörälä K. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J. 1991;12(3):315.
3. Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocrine Rev. 2006;27(1):47.
4. Taub PR, Gabbai-Saldate P, Maisel A. Biomarkers of heart failure. Congest Heart Fail. 2010;16(suppl 1):S19-S24.
5. Maisel A, Koon J, Krishnaswamy P. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J. 2001;141(3):367-374.
6. Novo G, Amoroso GR, Fazio G, Sutera F, Novo S. Biomarkers in heart failure. Front Biosci. 2009;14:2484-2493.
7. Cowie MR, Jourdain P, Maisel A, et al. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J. 2003;24(19):1710.
8. McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from breathing not properly (BNP) multinational study. Circulation. 2002;106(4):416-422.
9. Maisel A, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161-167.
10. Januzzi JL Jr, Camargo CA, Anwaruddin S, et al. The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005;95(8):948-954.
11. Baggish AL, van Kimmenade R, Bayes-Genis A, et al. Hemoglobin and N-terminal pro-brain natriuretic peptide: independent and synergistic predictors of mortality in patients with acute heart failure: results from the international collaborative of NT-proBNP (ICON) study. Clinica Chimica Acta. 2007;381(2):145-150.
12. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004;350(7):647-654.
13. Wang CS, FitzGerald JM, Schulzer M, Mak E, Ayas NT. Does this dyspneic patient in the emergency department have congestive heart failure? JAMA. 2005;294(15):1944.
14. Maisel A, Hollander JE, Guss D, et al. Primary results of the rapid emergency department heart failure outpatient trial (REDHOT): a multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol. 2004;44(6):1328-1333.
15. Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart. 2006;92(6):843-849.
16. Cheng V, Kazanagra R, Garcia A. A rapid bedside test for B-type natriuretic peptide predicts treatment outcomes in patients admitted with decompensated heart failure. J Am Coll Cardiol. 2001;37(2):386-391.
17. Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of readmission after decompensated heart failure. J Am Coll Cardiol. 2004;43(4):635-641.
18. Verdiani V, Nozzoli C, Bacci F, et al. Pre-discharge B-type natriuretic peptide predicts early recurrence of decompensated heart failure in patients admitted to a general medical unit. Eur J Heart Fail. 2005;7(4): 566-571.
19. Felker GM, Petersen JW, Mark DB. Natriuretic peptides in the diagnosisand management of heart failure. Can Med Assoc J. 2006;175(6): 611-617.
20. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ. 2005;330(7492):625.
21. Noveanu M, Breidthardt T, Potocki M, et al. Direct comparison of serial B-type natriuretic peptide and NT-proBNP levels for prediction of short-and long-term outcome in acute decompensated heart failure. Crit Care. 2011;15(1):R1.
22. Zugck C, Haunstetter A, Krüger C, et al. Impact of beta-blocker treatment on the prognostic value of currently used risk predictors in congestive heart failure. J Am Coll Cardiol. 2002;39(10):1615-1622.
23. Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA. N-terminal pro-brain natriuretic peptide. Eur Heart J. 2003;24(19):1735-1743.
24. Bayés-Genís A, Santaló-Bel M, Zapico-Muñiz E, et al. N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. Eur J Heart Fail. 2004;6(3):301-308.
25. Di Somma S, Magrini L, Mazzone M, et al. Decrease in NTproBNP plasma levels indicates clinical improvement of acute decompensated heart failure. Am J Emerg Med. 2007;25(3):335-339.
26. Bettencourt P, Azevedo A, Pimenta J, Friões F, Ferreira S, Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004;110(15):2168-2174.
27. Di Somma S, Magrini L, Pittoni V, et al. In-hospital percentage BNP reduction is highly predictive for adverse events in patients admitted for acute heart failure: The Italian RED study. Crit Care. 2010;14(3):R116.
28. Bayés-Genís A, Lopez L, Zapico E, et al. NT-ProBNP reduction percentage during admission for acutely decompensated heart failure predicts long-term cardiovascular mortality. J Card Fail. 2005; 11(5 suppl):S3-S8.
29. Bettencourt P, Januzzi JL Jr. Amino-terminal pro-B-type natriuretic peptide testing for inpatient monitoring and treatment guidance of acute destabilized heart failure. Am J Cardiol. 2008;101(3):S67-S71.
30. Parissis JT, Nikolaou M, Birmpa D, et al. Clinical and prognostic value of duke's activity status index along with plasma B-type natriuretic peptide levels in chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 2009;103(1):73-75.
31. Parissis JT, Nikolaou M, Farmakis D, et al. Clinical and prognostic implications of self-rating depression scales and plasma B-type natriuretic peptide in hospitalised patients with chronic heart failure. Heart. 2008;94(5):585-589.
32. Herrmann-Lingen C, Binder L, Klinge M, et al. High plasma levels of N-terminal pro-atrial natriuretic peptide associated with low anxiety in severe heart failure. Psychosom Medicine. 2003;65(4):517-522.
33. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlledrelease metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). JAMA. 2000;283(10): 1295-1302.
34. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet. 1999;353(9146):9-13.
35. Swedberg K, Kjekshus J. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). Am J Cardiol. 1988;62(2): 60A-66A.
36. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991;325(5):293-302.
37. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709-717.
38. Richards AM, Crozier IG, Yandle TG, Espiner EA, Ikram H, Nicholls MG. Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br Heart J. 1993;69(5):414.
39. Haug C, Metzele A, Kochs M, Hombach V, Grünert A. Plasma brain natriuretic peptide and atrial natriuretic peptide concentrations correlate with left ventricular end-diastolic pressure. Clin Cardiol. 1993; 16(7):553-557.
40. Morita E, Yasue H, Yoshimura M, et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation. 1993;88(1):82-91.
41. Yoshimura M, Yasue H, Okumura K, et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation. 1993;87(2): 464-469.
42. Tsutamoto T, Wada A, Maeda K, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol. 2001;37(5): 1228-1233.
43. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation. 1999;100(10):1056-1064.
44. Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2003;107(9): 1278-1283.
45. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355(9210):1126-1130.
46. Jourdain P, Jondeau G, Funck F, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP multicenter study. J Am Coll Cardiol. 2007;49(16): 1733-1739.
47. Lainchbury JG, Troughton RW, Strangman KM, et al. N-terminal pro- B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol. 2009;55(1):53-60.
48. Porapakkham P, Porapakkham P, Zimmet H, Billah B, Krum H. B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med. 2010;170(6):507-514.
49. Bhardwaj A, Rehman SU, Mohammed A, Baggish AL, Moore SA, Januzzi JL Jr. Design and methods of the pro-B type natriuretic peptide outpatient tailored chronic heart failure therapy (PROTECT) study. Am Heart J. 2010;159(4):532-538.e1.
50. Shah MR. STARBRITE: A randomized pilot trial of BNP-guided therapy in patients with advanced heart failure. Circulation. 2006;114(18 suppl):II_528.
51. Persson H, Erntell H, Eriksson B, Johansson G, Swedberg K, Dahlström U. Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT-proBNP Guided Management of Heart Failure-SIGNAL-HF (Swedish Intervention study-Guidelines and NT-proBNP AnaLysis in Heart Failure). Eur J Heart Fail. 2010;12(12):1300-1308.
52. Pfisterer M, Buser P, Rickli H, et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA. 2009;301(4):383-392.
53. Cowie MR, Struthers AD, Wood DA. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997;350(9088):1349-1353.
54. Wright SP, Doughty RN, Pearl A. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. J Am Coll Cardiol. 2003;42(10):1793-1800.
55. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction. Circulation. 2004;109(25): 3176-3181.
56. Heeschen C, Hamm CW, Mitrovic V, Lantelme NH, White HD. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation. 2004;110(20):3206-3212.
57. Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol. 2002;40(3):437-445.
58. Richards AM, Nicholls MG, Espiner EA, et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation. 2003;107(22):2786-2792.
59. Gerber IL, Stewart RA, Legget ME. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation. 2003;107(14):1884-1890.
60. Weber M, Arnold R, Rau M, et al. Relation of N-terminal pro B-type natriuretic peptide to progression of aortic valve disease. Eur Heart J. 2005;26(10):1023.
61. Bergler-Klein J, Klaar U, Heger M. Natriuretic peptides predict symptom- free survival and postoperative outcome in severe aortic stenosis. Circulation. 2004;109(19):2302.
62. Maisel A. B-type natriuretic peptide measurements in diagnosing congestive heart failure in the dyspneic emergency department patient. Rev Cardiovasc Med. 2002;3(suppl 4):S10-S17.